脑膜瘤:2021年世界卫生组织中枢神经系统肿瘤分类的分子更新及其影像学关联
脑膜瘤是最常见的原发性颅内肿瘤,占原发性中枢神经系统肿瘤的三分之一以上。2021年第五版世界卫生组织中枢神经系统肿瘤分类在保留原有分级系统的基础上,扩展了脑膜瘤的分子信息以指导管理,将端粒酶逆转录酶启动子突变和细胞周期蛋白依赖性激酶抑制剂2A/B缺失列为3级脑膜瘤的标志。本文综述了脑膜瘤不断演变的分子景观,强调与神经放射科医生相关的影像/遗传生物标志物及治疗策略。
要点
- 端粒酶逆转录酶启动子突变和细胞周期蛋白依赖性激酶抑制剂2A/B缺失现提示为3级脑膜瘤,复发风险增加。
- 肿瘤位置与潜在突变相关:大脑凸面和多数椎管内脑膜瘤携带22q缺失和/或NF2突变,颅底脑膜瘤则有AKT1、TRAF7、SMO和/或PIK3CA突变。
- MRI是诊断和治疗规划脑膜瘤的主要影像技术,DOTATATE PET成像可提供超越解剖成像的补充信息。
核心结论
- 2021年世界卫生组织中枢神经系统肿瘤分类在保留原有分级系统的基础上,扩展了脑膜瘤的分子信息以指导管理,将端粒酶逆转录酶启动子突变和细胞周期蛋白依赖性激酶抑制剂2A/B缺失列为3级脑膜瘤的标志;肿瘤位置与潜在突变相关;MRI是主要影像技术,DOTATATE PET可提供补充信息。
研究设计与样本
- 综述,检索范围与纳入文献数原文未报告。
关键影像表现/征象
- 大脑凸面和多数椎管内脑膜瘤携带22q缺失和/或NF2突变。
- 颅底脑膜瘤有AKT1、TRAF7、SMO和/或PIK3CA突变。
诊断标准与关键数值
- 2021年世界卫生组织中枢神经系统肿瘤分类基于组织病理学标准和分子谱将脑膜瘤分为3级(1-3级)。
- 端粒酶逆转录酶启动子突变和细胞周期蛋白依赖性激酶抑制剂2A/B缺失现提示为3级脑膜瘤,复发风险增加。
临床应用与阅片要点
- MRI是诊断和治疗规划脑膜瘤的主要影像技术。
- DOTATATE PET成像可提供超越解剖成像的补充信息。
- 本文强调与神经放射科医生相关的影像/遗传生物标志物及治疗策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Meningiomas, the most common primary intracranial neoplasms, account for more than one-third of primary CNS tumors. While traditionally viewed as benign, meningiomas can be associated with considerable morbidity, and specific meningioma subgroups display more aggressive behavior with higher recurrence rates. The risk stratification for recurrence has been primarily associated with the World Health Organization (WHO) histopathologic grade and extent of resection. However, a growing body of literature has highlighted the value of molecular characteristics in assessing recurrence risk. While maintaining the previous classification system, the 5th edition of the 2021 WHO Classification of Central Nervous System tumors (CNS5) book expands upon the molecular information in meningiomas to help guide management. The WHO CNS5 stratifies meningioma into 3 grades (1-3) based on histopathology criteria and molecular profile. The telomerase reverse transcriptase promoter mutations and cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) deletions now signify a grade 3 meningioma with increased recurrence risk. Tumor location also correlates with underlying mutations. Cerebral convexity and most spinal meningiomas carry a 22q deletion and/or NF2 mutations, while skull base meningiomas have AKT1, TRAF7, SMO, and/or PIK3CA mutations. MRI is the primary imaging technique for diagnosing and treatment-planning of meningiomas, while DOTATATE PET imaging offers supplementary information beyond anatomic imaging. Herein, we review the evolving molecular landscape of meningiomas, emphasizing imaging/genetic biomarkers and treatment strategies relevant to neuroradiologists.
引用
- Soni N, Ora M, Bathla G, et al. Meningioma: Molecular Updates from the 2021 World Health Organization Classification of CNS Tumors and Imaging Correlates. AJNR Am J Neuroradiol. 2025. PMID: 38844366. doi:10.3174/ajnr.A8368
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。